Recent Quotes

My Watchlist

Indicators

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.27 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	502
Open	53.27
Bid (Size)	53.78 (15)
Ask (Size)	53.82 (16)
Prev. Close	53.27
Today's Range	53.27 - 53.27
52wk Range	45.00 - 58.97
Shares Outstanding	1,250,690,553
Dividend Yield	3.57%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes

November 01, 2024

Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.

Via Benzinga

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

October 31, 2024

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.

Via Benzinga

Performance

YTD	+6.54%	+6.54%
1 Month	-3.97%	-3.97%
3 Month	+3.54%	+3.54%
6 Month	+7.99%	+7.99%
1 Year	+17.75%	+17.75%

More News

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

October 28, 2024

Via The Motley Fool

Why Sanofi Stock Flew Higher on Friday

October 25, 2024

Via The Motley Fool

Sanofi (SNY) Q3 2024 Earnings Call Transcript

October 25, 2024

Via The Motley Fool

Sanofi's Earnings Outlook

October 24, 2024

Via Benzinga

NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.

October 03, 2024

Via Chartmill

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

October 25, 2024

Via Benzinga

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat

October 25, 2024

Via Investor's Business Daily

Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast

October 25, 2024

Via Benzinga

Markets Mixed Again; DECK, SKX Beat After The Bell

October 25, 2024

Via Talk Markets

Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business

October 21, 2024

Via Benzinga

This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

October 21, 2024

Via The Motley Fool

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer

October 18, 2024

Via Benzinga

France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block

October 18, 2024

Via Benzinga

Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R

October 15, 2024

Via Benzinga

World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice

October 11, 2024

Via Benzinga

Denali Therapeutics Stock Is Sliding After The Bell: Here's Why

October 10, 2024

Via Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

October 07, 2024

Via Benzinga

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

October 07, 2024

Via The Motley Fool

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report

October 04, 2024

Via Benzinga

Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati

October 04, 2024

Via Benzinga

Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses

October 04, 2024

Via Benzinga

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next

October 01, 2024

Via Benzinga

Week In Review: Zenas Raises $259 Million In IPO

September 28, 2024

Via Talk Markets

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.